 SAN DIEGO--BUSINESS WIRE--Acadia Pharmaceuticals Inc. Nasdaq: ACAD announced today that the New England Journal of Medicine published results from the Phase 3 HARMONY study, an international, double-blind, placebo-controlled relapse prevention trial in 392 patients evaluating pimavanserin as an investigational treatment in patients with hallucinations and delusions associated with dementia-related psychosis DRP. The study included patients across five subgroups of dementia: Alzheimers di 